Bayer hikes Nubeqa's peak sales to more than €3B on prostate cancer data, teeing up new 3-way battle against Pfizer-Astellas, J&J

Bayer is spelling out an even more bullish estimate for Nubeqa’s blockbuster potential, thanks to a trial win in a new prostate cancer frontier for the drug. But the German drugmaker still faces an uphill fight against two formidable incumbent players.

Bayer has significantly dialed up Nubeqa’s peak sales estimate to over 3 billion euros ($3.4 billion), compared with the previous 1 billion euros. The new number is buoyed by a late-stage study showing that adding Nubeqa to androgen deprivation therapy (ADT) and the chemotherapy docetaxel significantly extended the lives of patients with metastatic hormone-sensitive prostate cancer (mHSPC).